A targeted IL-2 variant from Roche (SIX:ROG; OTCQX:RHHBY) showed monotherapy activity in patients with metastatic solid tumors in a Phase I trial. Data presented at the European Society for Medical Oncology in Munich from the Phase I BP29842 trial showed that the IL-2 variant, dubbed RO6874281, led to a complete response in a recurrent, heavily pretreated head and neck squamous cell carcinoma (SCC) patient, plus two partial responses, including a patient with cutaneous melanoma and a patient with mucosal melanoma.
The ESMO data also showed that RO6874281 produced one case of stable disease in a patient with penile SCC. The dose-escalation portion of the trial, which enrolled 30 patients with metastatic solid tumors, identified once-weekly 20 mg IV RO6874281 as the recommended dose after an initial 15 mg dose. Roche is enrolling patients with refractory melanoma and SCCs in an extension cohort of the trial...
BCIQ Target Profiles